The Liquid Biopsy and Tumor Progression in Breast Cancer
121 – 130 of 139
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Myoepithelium assessment with p63 immunostaining in formalinfixed paraffin-embedded breast cancer tissue pre-treated with RNA-later
- Contribution to journal › Published meeting abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffinblocks for estrogen receptor evaluation
- Contribution to journal › Published meeting abstract
-
Mark
Androgen receptor expression and breast cancer mortality in a population-based prospective cohort
- Contribution to journal › Article
-
Mark
Abstract P1-07-17: The SCAN-B study: 5-year summary of a large-scale population-based prospective breast cancer translational genomics platform covering a wide geography of Sweden (NCT02306096)
- Contribution to journal › Published meeting abstract
-
Mark
AIB1 is a new putative prognostic biomarker in the luminal A and B-like (HER2-negative) classification of invasive lobular carcinoma
- Contribution to conference › Abstract
-
Mark
Quality of up to 35 years old archival breast cancer tissue in paraffin-blocks for estrogen receptor evaluation
- Contribution to journal › Published meeting abstract
- 2016
-
Mark
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
- Contribution to journal › Article
-
Mark
Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort
- Contribution to journal › Article
-
Mark
A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation
- Contribution to journal › Article
-
Mark
Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer : Long-Term follow-up (> 25 years) of the phase III SBII:2pre trial
- Contribution to journal › Article
